FDA approves Amgen’s Prolia for new use

People suffering from osteoporosis experience severe weakening and thinning of bones.

Prolia currently has U.S. approval to treat postmenopausal women with osteoporosis at high risk for fracture. The drug brought in sales of $120 million to Amgen between April and June, up 36 percent sequentially.

According to the National Osteoporosis Foundation, two million men in the U.S. have osteoporosis and another 12 million are at risk, Amgen said in a statement.

(Reporting by Zeba Siddiqui in Bangalore)

http://reut.rs/Um7nvV

• Category
• Health update

• Tags

• By
• Hitap

Related Posts

HITAP Foundation at PMAC 2025: Advancing AI-Driven Solutions for a Healthier World

Limited resources and cutting-edge technology infiltrating every role mark the beginning of the health prioritization at the “Priorities 2024 Conference.

As our planet is with limited resources, health services to be provided must be prioritized.